These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35621626)

  • 1.
    Cho YA; Ko SY; Suh YJ; Kim S; Park JH; Park HR; Seo J; Choi HG; Kang HS; Lim H; Park HY; Kwon MJ
    Curr Oncol; 2022 Apr; 29(5):2895-2908. PubMed ID: 35621626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma.
    Lee HK; Kwon MJ; Ra YJ; Lee HS; Kim HS; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Min KW; Kang SY
    Diagn Pathol; 2020 Oct; 15(1):126. PubMed ID: 33054840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comprehensive assessment of mismatch repair and microsatellite instability status in molecular classification of endometrial carcinoma].
    Liu Y; Wang YX; Sun XJ; Ting X; Wu R; Liu XD; Liu CR
    Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):755-765. PubMed ID: 37849256
    [No Abstract]   [Full Text] [Related]  

  • 4. Triple-Negative Breast Cancer: Intact Mismatch Repair and Partial Co-Expression of PD-L1 and LAG-3.
    Wu S; Shi X; Wang J; Wang X; Liu Y; Luo Y; Mao F; Zeng X
    Front Immunol; 2021; 12():561793. PubMed ID: 33717059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers.
    Barrett MT; Lenkiewicz E; Malasi S; Basu A; Yearley JH; Annamalai L; McCullough AE; Kosiorek HE; Narang P; Wilson Sayres MA; Chen M; Anderson KS; Pockaj BA
    Breast Cancer Res; 2018 Jul; 20(1):71. PubMed ID: 29996881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer.
    Zang YS; Dai C; Xu X; Cai X; Wang G; Wei J; Wu A; Sun W; Jiao S; Xu Q
    Cancer Med; 2019 Aug; 8(10):4699-4708. PubMed ID: 31270941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
    Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
    Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer.
    Zhang L; Wang Y; Li Z; Lin D; Liu Y; Zhou L; Wang D; Wu A; Li Z
    Diagn Pathol; 2021 May; 16(1):38. PubMed ID: 33933102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microsatellite instability and mismatch repair protein expressions in lymphocyte-predominant breast cancer.
    Horimoto Y; Thinzar Hlaing M; Saeki H; Kitano S; Nakai K; Sasaki R; Kurisaki-Arakawa A; Arakawa A; Otsuji N; Matsuoka S; Tokuda E; Arai M; Saito M
    Cancer Sci; 2020 Jul; 111(7):2647-2654. PubMed ID: 32449246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of tumor-infiltrating lymphocytes, PD-L1, and
    Reznitsky FM; Jensen JD; Knoop A; Jensen MB; Laenkholm AV
    Acta Oncol; 2023 Dec; 62(12):1913-1920. PubMed ID: 37961947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in histological features and PD-L1 expression between sporadic microsatellite instability and Lynch-syndrome-associated disease in Japanese patients with colorectal cancer.
    Yamada R; Yamaguchi T; Iijima T; Wakaume R; Takao M; Koizumi K; Hishima T; Horiguchi SI
    Int J Clin Oncol; 2018 Jun; 23(3):504-513. PubMed ID: 29327160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive Immuno-Molecular Profiles for Liposarcoma: Roles of Programmed Death Ligand 1, Microsatellite Instability, and PIK3CA.
    Jeon HM; Lee JS; Kim SH; Yun KH; Park KH; Jeon MK; Lee YH; Yoon HI; Suh JS; Hur H; Kim KS; Kim S; Kim SH; Kim HS
    Oncology; 2020; 98(11):817-826. PubMed ID: 32892196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial.
    Di Bartolomeo M; Morano F; Raimondi A; Miceli R; Corallo S; Tamborini E; Perrone F; Antista M; Niger M; Pellegrinelli A; Randon G; Pagani F; Martinetti A; Fucà G; Pietrantonio F;
    Oncologist; 2020 Mar; 25(3):e460-e468. PubMed ID: 32162808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PIK3CA mutation subtype delineates distinct immune profiles in gastric carcinoma.
    Choi S; Kim H; Heo YJ; Kang SY; Ahn S; Lee J; Kim KM
    J Pathol; 2023 Aug; 260(4):443-454. PubMed ID: 37341658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expression level and prognostic value of PD-L1 in microsatellite instability-high gastric cancer].
    Wang XY; Hu YJ; Dong K; Zhao C; Huang XZ; Lian SY; Sun Y
    Zhonghua Bing Li Xue Za Zhi; 2020 Nov; 49(11):1114-1119. PubMed ID: 33152814
    [No Abstract]   [Full Text] [Related]  

  • 16.
    Guarneri V; Dieci MV; Bisagni G; Brandes AA; Frassoldati A; Cavanna L; Musolino A; Giotta F; Rimanti A; Garrone O; Bertone E; Cagossi K; Nanni O; Piacentini F; Orvieto E; Griguolo G; Curtarello M; Urso L; Paré L; Chic N; D'Amico R; Prat A; Conte P
    Clin Cancer Res; 2020 Nov; 26(22):5843-5851. PubMed ID: 32843527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer.
    Xiao X; Dong D; He W; Song L; Wang Q; Yue J; Xie L
    Gynecol Oncol; 2018 Apr; 149(1):146-154. PubMed ID: 29496294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microsatellite instability (MSI-H) is associated with a high immunoscore but not with PD-L1 expression or increased survival in patients (pts.) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (ox) and fluoropyrimidine (FP) with and without bevacizumab (bev): a pooled analysis of the AIO KRK 0207 and RO91 trials.
    Noepel-Duennebacke S; Juette H; Schulmann K; Graeven U; Porschen R; Stoehlmacher J; Hegewisch-Becker S; Raulf A; Arnold D; Reinacher-Schick A; Tannapfel A
    J Cancer Res Clin Oncol; 2021 Oct; 147(10):3063-3072. PubMed ID: 33675399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.
    Abida W; Cheng ML; Armenia J; Middha S; Autio KA; Vargas HA; Rathkopf D; Morris MJ; Danila DC; Slovin SF; Carbone E; Barnett ES; Hullings M; Hechtman JF; Zehir A; Shia J; Jonsson P; Stadler ZK; Srinivasan P; Laudone VP; Reuter V; Wolchok JD; Socci ND; Taylor BS; Berger MF; Kantoff PW; Sawyers CL; Schultz N; Solit DB; Gopalan A; Scher HI
    JAMA Oncol; 2019 Apr; 5(4):471-478. PubMed ID: 30589920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer.
    Tury S; Becette V; Assayag F; Vacher S; Benoist C; Kamal M; Marangoni E; Bièche I; Lerebours F; Callens C
    Oncotarget; 2016 Dec; 7(51):85124-85141. PubMed ID: 27835884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.